Tod M. Woolf
Präsident bei IPIFINI, Inc.
Profil
Tod M.
Woolf was the founder of Galena Biopharma, Inc. (founded in 2005) and Sequitur, Inc. (founded in 1996) where he held the title of President & Chief Executive Officer and Chief Executive Officer respectively.
Currently, he is the President at IPIFINI, Inc. (since 2004).
Dr. Woolf received a doctorate degree from Harvard University in 1991 and a graduate degree from Harvard University in 1988.
Aktive Positionen von Tod M. Woolf
| Unternehmen | Position | Beginn |
|---|---|---|
| IPIFINI, Inc. | Präsident | 01.01.2004 |
Ehemalige bekannte Positionen von Tod M. Woolf
| Unternehmen | Position | Ende |
|---|---|---|
Galena Biopharma, Inc.
 Galena Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Galena Biopharma, Inc. is a biopharmaceutical company, which develops and commercializes hematology and oncology therapeutics that address unmet medical needs. The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Its products include Abstral sublingual tablets and Zuplenz oral soluble film. The company was founded by Craig Mello on April 3, 2006 and is headquartered in San Ramon, CA. | Gründer | 05.11.2009 |
Sequitur, Inc.
 Sequitur, Inc. Miscellaneous Commercial ServicesCommercial Services Sequitur, Inc. provided drug discovery and disease research services. The company was headquartered in Huntington Beach, CA. | Gründer | - |
Ausbildung von Tod M. Woolf
| Harvard University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Galena Biopharma, Inc.
Galena Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Galena Biopharma, Inc. is a biopharmaceutical company, which develops and commercializes hematology and oncology therapeutics that address unmet medical needs. The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Its products include Abstral sublingual tablets and Zuplenz oral soluble film. The company was founded by Craig Mello on April 3, 2006 and is headquartered in San Ramon, CA. | Health Technology |
Sequitur, Inc.
Sequitur, Inc. Miscellaneous Commercial ServicesCommercial Services Sequitur, Inc. provided drug discovery and disease research services. The company was headquartered in Huntington Beach, CA. | Commercial Services |
| IPIFINI, Inc. |
